Armata Pharmaceuticals, Inc. (FRA:TG1N)
Germany · Delayed Price · Currency is EUR 6.15
0.00 (0.00%)
At close: Nov 28, 2025
Armata Pharmaceuticals Company Description
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide.
It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents.
The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Armata Pharmaceuticals, Inc.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 60 |
| CEO | Deborah Birx |
Contact Details
Address: 5005 McConnell Avenue Los Angeles, Washington 90066 United States | |
| Phone | 310 665 2928 |
| Website | armatapharma.com |
Stock Details
| Ticker Symbol | TG1N |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Deborah Birx | Chief Executive Officer |
| David House | Chief Financial Officer |
| Peter Hubbard | Chief Operating Officer |